Long-term safety and efficacy of oral phentolamine mesylate (Vasomax®) in men with mild to moderate erectile dysfunction

Vasomax Study Group

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

The objectives of this study were to evaluate long-term safety and efficacy of phentolamine mesylate, an orally active, rapid-acting alpha-adrenergic receptor antagonist, for the treatment of men suffering from erectile dysfunction (ED). It was an open-label study involving more than 2000 patients. Men received phentolamine mesylate 40 mg or 80 mg (10 tablets/month) as needed for up to 13 months and self-assessed erectile performance using two validated questionnaires. Treatment with phentolamine mesylate was associated with increases in Erectile Function Domain score of the IIEF, successful vaginal penetrations, and in overall satisfaction. Most adverse events were mild or moderate in severity and consistent with the known pharmacodynamic properties of phentolamine. In conclusion, phentolamine mesylate is safe and effective in the long-term treatment of men with mild to moderate ED.

Original languageEnglish (US)
Pages (from-to)266-270
Number of pages5
JournalInternational Journal of Impotence Research
Volume14
Issue number4
DOIs
StatePublished - 2002

Keywords

  • Alpha adrenoreceptors
  • Erectile dysfunction
  • International Index of Erectile Function
  • Phentolamine mesylate
  • Sexual Encounter Profile
  • Tolerability

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Long-term safety and efficacy of oral phentolamine mesylate (Vasomax®) in men with mild to moderate erectile dysfunction'. Together they form a unique fingerprint.

Cite this